Onera receives CE mark for innovative sleep PSG system
EINDHOVEN: Onera Health, a privately held medical technology company, announced today that its wholly-owned subsidiary in the Netherlands, Onera B.V., has received a CE Certificate of Conformity for its patch-based Sleep Test System (STS) that brings the gold-standard quality of a hospital diagnostic system directly to a user’s home. The CE mark allows the groundbreaking PSG device to be sold in the European market. As well as securing a CE mark in the EU, Onera is currently awaiting 510(k) clearance from the US Food and Drug Administration for its PSG system. During the upcoming months, Onera will focus on strategic partnerships with exclusive European and American partners to evaluate the potential of the product and patched-based technology.
Onera’s medical-grade technology is a huge step forward in transforming the outdated, cumbersome, and expensive process of traditional sleep testing, which is partly responsible for the underdiagnosis of sleep disorders, which are estimated to occur in one in five people worldwide. Different configurations of Onera’s non-invasive, compact, and portable medical device offer comprehensive data to support the diagnosis of various sleep disorders and enable clinicians to remotely monitor and optimize patients’ treatment. Onera’s innovative and convenient patch-based device can reduce procedural delays in sleep testing due to the space crisis and challenges in accessing healthcare professionals. The user-centric technology enables not only at-home diagnostics but also offers opportunities for hospitals that have limited or no access to a sleep clinic to implement sleep diagnostic testing within their institution.
“By obtaining the CE mark Onera has achieved a critical regulatory milestone which is an important step toward delivering on our promise to make sleep testing more convenient, easy-to-use and accessible to everyone, anywhere – even in the patient’s home! We are now in a position to introduce Onera’s technology in various configurations to the European market, working closely with doctors from different areas in medicine, beginning with exclusive partnerships in The Netherlands, Germany, and Italy while we continue to explore other geographies. Simultaneously are we awaiting the pending FDA approval for authorization in the US.”, said Ruben de Francisco, Founder, CTO & interim CEO of Onera.
